JP2015164953A5 - - Google Patents

Download PDF

Info

Publication number
JP2015164953A5
JP2015164953A5 JP2015115856A JP2015115856A JP2015164953A5 JP 2015164953 A5 JP2015164953 A5 JP 2015164953A5 JP 2015115856 A JP2015115856 A JP 2015115856A JP 2015115856 A JP2015115856 A JP 2015115856A JP 2015164953 A5 JP2015164953 A5 JP 2015164953A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administration
composition according
subject
reduces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015115856A
Other languages
English (en)
Japanese (ja)
Other versions
JP6157539B2 (ja
JP2015164953A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015164953A publication Critical patent/JP2015164953A/ja
Publication of JP2015164953A5 publication Critical patent/JP2015164953A5/ja
Application granted granted Critical
Publication of JP6157539B2 publication Critical patent/JP6157539B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015115856A 2005-09-16 2015-06-08 Cd36の発現を減少させる方法 Active JP6157539B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71817005P 2005-09-16 2005-09-16
US60/718,170 2005-09-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012181082A Division JP5805596B2 (ja) 2005-09-16 2012-08-17 Cd36の発現を減少させる方法

Publications (3)

Publication Number Publication Date
JP2015164953A JP2015164953A (ja) 2015-09-17
JP2015164953A5 true JP2015164953A5 (https=) 2016-01-14
JP6157539B2 JP6157539B2 (ja) 2017-07-05

Family

ID=37889419

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2008531412A Active JP5416971B2 (ja) 2005-09-16 2006-09-18 Cd36の発現を減少させる方法
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Cd36の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Cd36の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Cd36の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Cd36の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Cd36の発現を減少させる方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2008531412A Active JP5416971B2 (ja) 2005-09-16 2006-09-18 Cd36の発現を減少させる方法
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Cd36の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Cd36の発現を減少させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Cd36の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Cd36の発現を減少させる方法

Country Status (10)

Country Link
US (10) US7541340B2 (https=)
EP (5) EP3095454A1 (https=)
JP (6) JP5416971B2 (https=)
KR (9) KR20150013353A (https=)
CN (6) CN104788540B (https=)
AU (1) AU2006292352B2 (https=)
CA (8) CA2622911C (https=)
DK (1) DK1931369T3 (https=)
HK (1) HK1206971A1 (https=)
WO (1) WO2007035640A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599216B9 (en) 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) * 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7687243B1 (en) * 2005-06-06 2010-03-30 Crook Tonia M Automated method for detecting apoptosis in cells
CN104788540B (zh) * 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
ES2964555T3 (es) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011153209A2 (en) * 2010-06-01 2011-12-08 Cornell University Cd36 inhibition to control obesity and insulin sensitivity
EP2590664B1 (en) * 2010-07-09 2019-03-27 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
CN104271146A (zh) * 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
JP2015529655A (ja) 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
PL2936151T3 (pl) * 2012-12-18 2018-11-30 Biocrine Ab Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
US9895410B2 (en) * 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
US20170007663A1 (en) * 2013-12-16 2017-01-12 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US11392555B2 (en) 2019-05-15 2022-07-19 Pure Storage, Inc. Cloud-based file services
WO2021021452A1 (en) * 2019-07-26 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University 1,8-cineol coated implants
WO2021101646A1 (en) 2019-11-20 2021-05-27 The Board Of Trustees Of The Leland Stanford Junior University Prophylactic skin treatment for radiation therapy
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
AU2024298726A1 (en) 2023-07-27 2026-02-19 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
DE10051983A1 (de) 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
EP1994941A3 (de) * 2000-10-20 2012-07-25 Hamburger Stiftung zur Förderung von Wissenschaft und Kultur Arzneimittel, enthaltend mindestens ein oxidiertes Protein
AU2002256092C1 (en) 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
AU2002360460A1 (en) * 2001-12-03 2003-06-17 Nuvelo, Inc. Methods and materials relating to novel polypeptides and polynucleotides
JP4346870B2 (ja) * 2002-07-05 2009-10-21 キッコーマン株式会社 血糖値上昇抑制用組成物
WO2004017986A1 (en) * 2002-08-23 2004-03-04 Valorisation-Recherche, Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
PL2604286T3 (pl) 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
US20050012597A1 (en) 2003-07-02 2005-01-20 Anderson Peter Traneus Wireless electromagnetic tracking system using a nonlinear passive transponder
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
EP1712125A4 (en) 2003-12-12 2009-06-10 Japan Science & Tech Agency ANIMAL MODEL Animal expressing MEGSIN / RAGE / iNOS AND METHOD FOR EVALUATING COMPOUNDS WITH THE HELP OF ANIMALS
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US8157123B2 (en) * 2005-02-23 2012-04-17 The Glad Products Company Container
CN104788540B (zh) 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en) 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
JP2012181082A (ja) * 2011-03-01 2012-09-20 Tokyo Electric Power Co Inc:The 仕切弁の分解点検補助装置およびその案内治具、並びに仕切弁の分解点検方法
CN202756379U (zh) 2012-07-13 2013-02-27 滨中元川金属制品(昆山)有限公司 一种自攻牙螺丝

Similar Documents

Publication Publication Date Title
JP2015164953A5 (https=)
JP2017066161A5 (https=)
HRP20251088T1 (hr) Upotreba dugodjelujućih peptida glp‑1
JP2016053040A5 (https=)
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
JP2012193216A5 (https=)
WO2011017195A3 (en) Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
JP2007262090A5 (https=)
NZ707640A (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
JP2016517421A5 (https=)
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
WO2014160216A3 (en) Dual targeting anticancer agents
JP2021529829A5 (https=)
JP2016527312A5 (ja) ヒスタミンh4受容体を介してもたらされた掻痒状態を治療するための医薬組成物
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
JP2007119497A5 (https=)
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
MX2015009681A (es) Un medicamento combinado que comprende finilefrina y paracetamol.
WO2014145199A3 (en) Retrograde delivery of sdf-1 for treatment of myocardial infarction